Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iBio (IBIO) EBITDA (2016 - 2025)

iBio (IBIO) has disclosed EBITDA for 16 consecutive years, with -$9.0 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 105.5% to -$9.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$24.8 million through Dec 2025, down 61.03% year-over-year, with the annual reading at -$18.6 million for FY2025, 11.83% down from the prior year.
  • EBITDA for Q4 2025 was -$9.0 million at iBio, down from -$5.7 million in the prior quarter.
  • The five-year high for EBITDA was -$3.4 million in Q2 2024, with the low at -$10.6 million in Q4 2022.
  • Average EBITDA over 5 years is -$6.3 million, with a median of -$5.5 million recorded in 2021.
  • The sharpest move saw EBITDA plummeted 222.26% in 2021, then skyrocketed 57.48% in 2023.
  • Over 5 years, EBITDA stood at -$7.2 million in 2021, then crashed by 46.22% to -$10.6 million in 2022, then surged by 57.48% to -$4.5 million in 2023, then grew by 2.94% to -$4.4 million in 2024, then tumbled by 105.5% to -$9.0 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$9.0 million, -$5.7 million, and -$5.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.